It’s readily apparent that medical writers charged with preparing dossiers for submission to regulatory authorities must be excellent communicators. But what’s less obvious is the degree to which other skills determine the success of the effort; project management expertise and leadership qualities are vital assets in medical writers.
Preparing a regulatory submission involves managing a multi-disciplinary team, setting clear goals, creating and adhering to a critical project schedule, and meeting quality standards. Much rests on how the medical writing team sets and shares a direction, plans tasks, coordinates multiple fast-moving activities, and resolves differences – all in addition to how they communicate an asset’s safety, efficacy, and suitability.
The ideal skillset
To excel, medical writers must demonstrate, beyond superior communication abilities:
- Attention to detail
- Creativity
- Project and time management expertise
- Proficiency with various software programs
The medical writing function can, of course, be outsourced to a partner employing specialists in the area. Indeed, from a recent webinar on the topic, we learned that approximately a third of the audience currently outsources medical writing, while another nine percent were exploring that as an option. Let’s review some of the most essential leadership qualities and practices that sponsors should expect from their medical writers, whether from in-house staff or a partner’s team.
Developing the project plan
Medical writers’ work begins long before the first key stroke. They must convene a kick-off meeting to train all involved on their role, explain the tasks ahead, and clarify the standards expected. They must then develop a project plan with input from all key stakeholders to define the scope of the project, assign responsibilities, and lay out a detailed timeline. The plan should include a storyboard of the key messages to be conveyed and a checklist that maps out who will provide what information for each module of the dossier.
Setting expectations and building consensus
Medical writers must brief reviewers at the onset of the project, ensuring that they share a common understanding of what is expected of them - not only in terms of how and when they will be called upon, but also in terms of the types of comments they should provide. Will their focus be on scientific accuracy, compliance, or formatting?
Providing regular updates
The entire, cross-functional submission team should continue to meet regularly over the course of the project to discuss the status of each component and identify issues proactively. Such regular check-in points allow all writers to stay informed, the leader to check on the progress of co-authors, and team members to share helpful tips and tricks.
Resolving conflicting comments
Addressing conflicting or non-consolidated comments from reviewers is typically one of the greatest and most time-consuming challenges medical writers face. By holding and facilitating structured comments resolution meetings (CRMs) (with mandatory attendance), the writing team can gain clarity on comments and seek alignment from reviewers. As a last step, reviewers should be gathered at a signature meeting to document their final approval.
Maintaining control of quality
Medical writers should be aiming for consistency in the terminology used in the dossier, the standards applied, and the information that flows from one document to the next. Such consistency is, in fact, the key driver in reducing errors and ensuring compliance with regulatory expectations. Effective methodologies for controlling quality include enlisting a team of reviewers who have not been involved in drafting the document, employing industry software for quality checks, and dispensing style guides, cheat sheets, and customised checklists to those reviewing and validating the documents.
Shortening the timeline
Without cutting corners or sacrificing quality, the preparation timeline can be as short as possible when medical writers practice a few “tricks of the trade” to keep the process moving efficiently. While this is far from an exhaustive list, much time can be saved by:
- Developing shell documents upfront that contain all of the necessary sections, minus any final study results. In this way, a great deal of approved text can be “locked down” so that it will not be revisited and revised in future review cycles
- Conducting quality control on a rolling basis as portions of the work reach maturity rather than waiting for the final stages when all components are done
- Using authoring and editing tools to support collaboration, document management, and the flow of information between modules.
As they usher a submission package through the various stages of compilation, review, quality control, editing, and completion, medical writing teams must have strong leaders who can set the direction for the project, ensure alignment across diverse stakeholders, promote transparency, and ensure accountability for meeting deadlines and quality standards. Through a combination of careful planning and ongoing project management, medical writers can minimise the risk of queries from regulators and delays in the document’s preparation and approval.
Ultimately, it is the combination of scientific expertise, project leadership, and proactive communication that empowers medical writers to deliver high quality submissions on time, with confidence, and with fewer regulatory hurdles.
For more information on ICON’s comprehensive medical writing solutions, visit ICONplc.com/medicalwriting.
Contact us to discover how our expertise can flexibly support your needs across all major areas.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel